



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Ralph A. Reisfeld et al.)
)
Application No. 10/090,183)
)
Filed: March 2, 2002) Group Art Unit: 1636
)
For: DNA VACCINE AGAINST)
PROLIFERATING ENDOTHELIAL)
CELLS AND METHODS OF USE)
THEREOF)
)
Examiner: Michael D. Burkhart) Attorney Docket No. TSRI 829.0

INFORMATION DISCLOSURE STATEMENT

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

This information disclosure statement is filed in order to call to the Examiner's attention certain publications that militate against the Examiner's stated position in the Office Action dated February 24, 2005 on the above-identified application. The publications are listed on the attached Form PTO/SB/08B.


Should a fee be required for consideration of the herein-identified prior art publications, kindly charge our Deposit Account No. 15-0508.

Respectfully submitted,

August 24, 2005

By 
Talivaldis Cepuritis (Reg. No. 20,818)

OLSON & HIERL, LTD.
20 North Wacker Drive
36th Floor
Chicago, Illinois 60606
(312) 580-1180



"Express Mail" Mailing Label No. EL637096533US

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/090,183
Filing Date	03/02/2002
First Named Inventor	Ralph A. Reisfeld
Art Unit	1636
Examiner Name	Michael D. Burkhardt
Attorney Docket Number	TSRI 829.0

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MARSHALL et al., J. Clin. Oncol. 23(4):720-31 (2005)	
		SCHLOM et al., Dev. Biol. (Basel) 116:27-47 (2004)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.